Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

Clinical trial NCT05397496 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05397496
Sponsor: Novartis Pharmaceuticals
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

B-cell Non-Hodgkin Lymphoma (B-NHL)B-cell Acute Lymphoblastic Leukemia (B-ALL)

Start date: 2022-10-03
Primary completion: 2027-01-04
Enrollment: 61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.